151733-96-9

Usage

Uses

Used in Pharmaceutical Research:
Ethyl 3-(difluoromethyl)-1H-pyrazole-4-carboxylate is used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique chemical structure allows it to be a valuable building block for the development of new drugs with potential therapeutic applications.
Used in Chemical Research:
As a research chemical, ethyl 3-(difluoromethyl)-1H-pyrazole-4-carboxylate is employed in the study of chemical reactions and mechanisms. Its reactivity and stability can provide insights into the behavior of similar compounds and contribute to the advancement of chemical knowledge.
Used in Material Science:
The compound may also find applications in the field of material science, where its properties can be exploited to develop new materials with specific characteristics, such as improved stability or enhanced performance in certain conditions.
Used in Agrochemicals:
Ethyl 3-(difluoromethyl)-1H-pyrazole-4-carboxylate could be utilized in the development of agrochemicals, such as pesticides or herbicides, due to its potential biological activity and ability to interact with target organisms.

Upstream product

• 176969-33-8 (E/Z)-ethyl 2-(ethoxymethylene)-4,4-difluoro-3-oxobutanoate 
• 16205-84-8 ethyl 3-(trimethylsilyl)propynoate 
• 352-24-9 ethyl 4,4-difluoro-3-oxobutyrate 
• 5941-50-4 ethyl β-nitroacrylate 
• 1086400-66-9 (Z)-2-(ethoxymethylene)-4,4-difluoro-3-oxobutanoic acid ethyl ester 

Downstream Products

• 141573-95-7 ethyl 3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxylate 
• 1373886-86-2 C₁₂H₁₀F₃N₃O 
• 581809-46-3 bixafen 

Relevant academic research and scientific papers

ASK1 INHIBITING AGENTS

Provided are compounds of Formula (I): Formula (I), including compounds of Formulas (II), (III), (IV), (V) and (VI), wherein X, R1, R2, R3, R4 and n are as defined herein,and pharmaceutically acceptable salts thereof, and methods for their use and production. These compounds can be useful, e.g., in the treatment of disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1).

A Unified Continuous Flow Assembly-Line Synthesis of Highly Substituted Pyrazoles and Pyrazolines

A rapid and modular continuous flow synthesis of highly functionalized fluorinated pyrazoles and pyrazolines has been developed. Flowing fluorinated amines through sequential reactor coils mediates diazoalkane formation and [3+2] cycloaddition to generate more than 30 azoles in a telescoped fashion. Pyrazole cores are then sequentially modified through additional reactor modules performing N-alkylation and arylation, deprotection, and amidation to install broad molecular diversity in short order. Continuous flow synthesis enables the safe handling of diazoalkanes at elevated temperatures, and the use of aryl alkyne dipolarphiles under catalyst-free conditions. This assembly-line synthesis provides a flexible approach for the synthesis of agrochemicals and pharmaceuticals, as demonstrated by a four-step, telescoped synthesis of measles therapeutic, AS-136A, in a total residence time of 31.7 min (1.76 g h?1).

Synthesis of Celecoxib, Mavacoxib, SC-560, Fluxapyroxad, and Bixafen Enabled by Continuous Flow Reaction Modules

Multi-step continuous flow synthesis enables a parallel approach to obtain agrochemicals and pharmaceuticals containing 3-fluoroalkyl pyrazole cores. In this system, fluorinated amines are transformed into pyrazole cores through a telescoped in situ generation and consumption of diazoalkanes. Once synthesized, additional continuous flow and batch reactions add complexity to the pyrazole core via C–N arylation and methylation, TMS cleavage, and amidation. Using this modular assembly line approach, Bixafen and Fluxapyroxad were synthesized in 38 % yield over four continuous flow steps in an overall reaction time of 56 min. Finally, coupling selected continuous flow processes with an offline (batch) Ullmann coupling afforded Celecoxib, Mavacoxib, and SC-560 in 33–54 % yield over two to three steps.

Synthesis method for 3-difluromethylation-1-methyl-1H-pyrazol-4-carboxylic acid ethyl ester

The invention relates to a synthesis method for a compound, in particular to a synthesis method for 3-difluromethylation-1-methyl-1H-pyrazol-4-carboxylic acid ethyl ester. The method comprises the steps that a water bath reaction is performed by taking 2-ethyoxyl methylene-4,4-difluoro acetoacetic ether and hydrazine hydrate as raw materials to prepare 3-difluromethylation-1H-pyrazol-4-carboxylic acid ethyl ester, the 3-difluromethylation-1H-pyrrole-4-carboxylic acid ethyl ester and dimethyl carbonate are subjected to an oil bath reaction, extraction is performed through methylbenzene, and then the 3-difluromethylation-1-methyl-1H-pyrazol-4-carboxylic acid ethyl ester is prepared. The method is mild in reaction condition and high in yield.

Preparation method of 3-fluoroalkyl-1H-pyrazole-4-formic ester

The invention provides a preparation method of 3-fluoroalkyl-1H-pyrazole-4-formic ester. Compared with the prior art, the preparation method comprises the steps of mixing 3-nitro acrylate shown in the formula (I), a fluoroalkyl diazo compound shown in the formula (II), a catalyst, an alkali compound in an organic solvent, and reacting to obtain the 3-fluoroalkyl-1H-pyrazole-4-formic ester shown in the formula (III). The preparation method provided by the invention is simple in operating steps, mild in reaction condition, high in yield, good in universality of a substrate, and meanwhile a product has higher purity.

5-MEMBERED HETEROCYCLIC AMIDES AND RELATED COMPOUNDS

5-Membered heterocyclic amides and related compounds are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly usef